The medical imaging market globally reached a value of \(36.9 billion in 2020 and is projected to hit \)56.53 billion by 2028, as reported by company filing analytics on GlobalData.
Flywheel, a US-based company specializing in AI-driven medical imaging platforms, has collaborated with Microsoft and NVIDIA to launch its software-as-a-service (SaaS) data management solution.
Since 2015, Flywheel’s SaaS has streamlined processes for data organization, aiding in the development of AI models and advancing health scanning research. The primary objective of medical imaging studies is to support life science companies, academic institutions, and healthcare professionals.
The global medical imaging market was valued at \(36.9 billion in 2020 and is expected to reach \)56.53 billion by 2028, with a compound annual growth rate (CAGR) of 5.8% from 2021 to 2030, based on insights from company filing analytics on GlobalData.
Dr. Richard Bruce, Associate Professor of Radiology and Radology Vice Chair of Informatics at the University of Wisconsin School of Medicine and Public Health, expresses enthusiasm for exploring how the integration of various technologies can enhance the speed and depth of research. The goal is to bridge the gap between technology and patient care in medical imaging to improve outcomes and increase accessibility to innovative care.
Trent Norris, Chief Revenue Officer at Flywheel, underscores the significance of the collaboration between Microsoft Azure Machine Learning, NVIDIA MONAI, and Microsoft’s services in advancing their objectives. This strategic alliance aims to showcase the versatility of AI solutions to researchers, clinicians, and scientists worldwide, accelerating research efforts and fostering innovation in healthcare.
Peter Durlach, Corporate Vice President for Health and Life Sciences at Microsoft, commends the team for their contributions to medical innovation. He believes that Flywheel’s expertise in medical imaging, combined with Azure’s capabilities and mPower’s imaging analytics, heralds a new era of progress in healthcare.
Flywheel has recently introduced new products, Flow and Discovery, in July 2022, enabling researchers to expedite clinical trials, identify specific cohorts, and analyze datasets efficiently.
